Sputolosin Oral Powder 5 mg/g

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Dembrexine hydrochloride

Disponível em:

Boehringer Ingelheim Ltd

Código ATC:

QR05CB90

DCI (Denominação Comum Internacional):

Dembrexine hydrochloride

Dosagem:

5 milligram(s)/gram

Forma farmacêutica:

Oral powder

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Horses

Área terapêutica:

dembrexine hydrochloride

Indicações terapêuticas:

Respiratory Tract preparations

Status de autorização:

Authorised

Data de autorização:

1990-10-01

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Sputolosin Oral Powder 5 mg/g
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains:
ACTIVE SUBSTANCE:
Dembrexine hydrochoride monohydrate
5 mg
(Equivalent to 4.372 mg of dembrexine per g.)
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral Powder.
Fine, white and free-flowing.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is indicated for the symptomatic treatment of acute,
sub-acute and chronic respiratory disease of the upper and
lower respiratory tract, where an abnormal amount of mucus of
increased viscosity is present.
4.3 CONTRAINDICATIONS
Do not use in animals known to be hypersensitive to the active
substance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
None known.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS:
Care/precautions should be taken when using this product to avoid skin
contact, eye contact and/or inhalation of the
dust.
Medical advice should be sought if you feel unwell after using this
product.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_6_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_4_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.